HUTCHMED (China) (HMDCF) Interest Expenses (2015 - 2021)
HUTCHMED (China)'s (HMDCF) quarterly Interest Expenses came in at -$1.1 million in Q2 2021, down 315.62% year-over-year from $493449.3 in Q2 2020, and down 181.47% quarter-over-quarter from $1.3 million in Q1 2021.
Powered by 
Analysis
HUTCHMED (China) (HMDCF) Interest Expenses (2015 - 2021) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Interest Expenses for 4 consecutive years, with -$1.1 million the latest figure, recorded in Q2 2021.
- On a quarterly basis, Interest Expenses fell 315.62% year-over-year to -$1.1 million in Q2 2021; TTM through Jun 2021 was $753000.0, a 45.09% increase from a year earlier, with the FY2025 full-year figure at -$2.9 million, changed 0.24% from the prior year.
- Interest Expenses was -$1.1 million for Q2 2021 at HUTCHMED (China), down from $1.3 million in the prior quarter.
- Over five years, Interest Expenses peaked at $1.3 million in Q1 2021 and troughed at -$1.1 million in Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.35 Bn | 198.36 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 181.19 Bn | 178.01 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.48 Bn | 124.62 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.59 Bn | 74.60 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 61.45 Bn | 56.27 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 54.89 Bn | 49.75 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.21 Bn | 30.90 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.38 Bn | 30.10 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.81 Bn | 29.81 Bn | 1.16 Mn | - |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | -1.06 Mn |
| Mar 31, 2021 | 1.31 Mn |
| Jun 30, 2020 | -256,000.00 |
| Mar 31, 2020 | 767,000.00 |
| Jun 30, 2016 | -87,000.00 |
| Jun 30, 2015 | 95,000.00 |